Bioverativ (Nasdaq: BIVV) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Feb. 14, 2017 --

What: 
Bioverativ (Nasdaq:BIVV), a newly independent, global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, John Cox, Chief Executive Officer, will ring the Opening Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Wednesday, February 15, 2017 – 9:15 a.m. to 9:30 a.m. ET        

Bioverativ Media Contact:
Tracy Vineis
(781) 663-4350
[email protected]

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq.

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live.

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq.

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/.

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About Bioverativ
Bioverativ (NASDAQ:BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.

-NDAQA-